VERV: Verve Therapeutics Inc. Market Capitalization-to-Revenue Ratio

Symbol and logo of brand Verve Therapeutics (VERV)

The price-to-sales ratio for Verve Therapeutics (VERV) reflects the asset's dynamics, where 16.60 serves as the current parameter value. Market capitalization growth is fueled by the recruitment of top CRISPR specialists through generous RSUs. Verve Therapeutics is implementing one-time liver gene editing for lifelong cholesterol control. However, the lack of revenue and the costs of precision testing temporarily limit the business's operating leverage.

VERV Verve Therapeutics Inc. Price-to-Revenue Ratio (11/14/2022 - 08/09/2025)

Metric breakdowns and analytics for vervetx.com (VERV)

- stock quotes and analyst forecast:
Price Verve Therapeutics, Inc.|VERV - Analyst Consensus Forecast
- market capitalization information:
Market Value Verve Therapeutics, Inc.|VERV - Enterprise Value
- book capitalization indicators:
Net Asset Value per Share Verve Therapeutics|VERV - Company Book Value|Market Value to Book Value vervetx.com|VERV - Company Total Assets
- debt obligations and liquidity statistics:
Total Debt to Capital Verve Therapeutics|VERV - Long-Term Debt to Equity|Current Liabilities to Equity Verve Therapeutics, Inc.|VERV - Company Aggregate Debts|Debts to Book Value Verve Therapeutics, Inc.|VERV - Company Long-Term Liabilities|Company Short-Term Debts Verve Therapeutics|Intermediate Liquidity Ratio vervetx.com
- earnings and multiples data:
VERV - Net Profit|Company Profit Forecast Verve Therapeutics|VERV - P/E Multiple|Projected Price to Earnings Verve Therapeutics Inc.|VERV - Price/Earnings to Growth Ratio|Total Company Value to Operating Income Before Depreciation Ratio Verve Therapeutics, Inc.|VERV - Operating profit before deduction of amortization|Earnings per share for the last twelve months Verve Therapeutics|VERV - Net earnings per share (EPS TTM)|Earnings per share growth in annualized terms for the last twelve months vervetx.com|VERV - Earnings per share growth in current year|Expected earnings per share trend next year Verve Therapeutics
- total revenue and sales volume data:
VERV - Company Sales|Company Projected Revenue Verve Therapeutics, Inc.|VERV - P/S Multiple|Forward Price to Sales Verve Therapeutics, Inc.
General company analysis:VERV - vervetx.com
Signature product of Verve Therapeutics

The P/S ratio reflects the market value of a business relative to its annual gross revenue, allowing an investor to assess the extent of the premium paid for future revenue growth rates. By analyzing historical P/S levels, one can see how the patent protection of Verve Therapeutics (VERV) gene-editing technologies justifies a high revenue premium, confirming its status as a technological leader in the treatment of cardiovascular pathologies.

Who Verve Therapeutics competes with

REGN (Regeneron Pharmaceuticals, Inc.) - Market Capitalization-to-Revenue Ratio|iRhythm Technologies Inc - Market Cap to Revenue|Price-to-Revenue Coefficient Lantheus Holdings, Inc. (LNTH)|MLYS - Price-to-Revenue Ratio|HeartFlow, Inc. (HTFL) - Market Cap to Revenue|KMTS: P/S Multiple|ESPR: Market Cap to Sales Volume|Price-to-Revenue Ratio Amarin|AVR: Market Capitalization-to-Revenue Ratio|P/S Multiple TNYA|CVRX (CVRx) - Market Capitalization-to-Revenue Ratio|P/S Multiple MIST (milestonepharma.com)|P/S Multiple Cardiol Therapeutics CRDL|BEAT: Market Cap to Revenue|TENX - P/S Multiple|ADGM (Adagio Medical Holdings) - Market Cap to Revenue|BCDA (BioCardia, Inc.) - Price-to-Revenue Ratio|VTAK (Catheter Precision Inc) - P/S Multiple|Price-to-Revenue Ratio ABIO|Market Cap to Revenue ACST (Acasti Pharma)|P/S Multiple Aerovate Therapeutics (AVTE)|Windtree Therapeutics, Inc. - Market Cap to Revenue